BOSTON — Ambrosia Bio and Ginkgo Bioworks are partnering to use Ginkgo’s Enzyme Services to formulate an expression strain for the production of Ambrosia Bio’s proprietary enzymes used for the conversion of feedstock into allulose, according to the company.

Allulose is an FDA-approved rare sugar found in figs, raisins, wheat, maple syrup, and molasses, that only occurs naturally in small amounts.

Ambrosia Bio has created a bioprocess using proprietary enzymes combined with a production process to affordably convert lower-margin feedstocks such as sugar and starch into sugars and ingredients such as allulose, according to the company.

Ginkgo Enzyme Services is an end-to-end service that features high throughput screening and machine learning-guided protein design, which will aid Ambrosia Bio in formulating an optimized version of its enzyme in a productive expression strain, according to the company.

“Ginkgo has established itself as a global leader in the synthetic biology ecosystem and precision fermentation space,” said Ziv Zwighaft, founder and chief executive officer at Ambrosia Bio. “With end-to-end capabilities, Ginkgo is a one-stop shop that can enable Ambrosia Bio to expand global allulose availability. We aim to provide affordable options for key sugar production players, as well as leading global brands in the food and beverage space, many of whom are looking for a sugar replacement that does not compromise the superb consumption experience offered by their products.”